Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia

Fertility and Sterility

Volumn 95, Issue 3, 2011, Pages

  Gómez, Raul ^a   Abad, Antonio ^b   Delgado, Francisco ^a   Tamarit, Silvia ^b   Simón, Carlos ^a   Pellicer, Antonio ^a,c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

angiogenesis; dopamine; dopamine agonists; dopamine receptor 2; Endometriosis; endometrium; quinagolide; VEGF; VEGF receptor 2

Indexed keywords

CHEMOKINE; CHEMOKINE CCL10; CHEMOKINE RECEPTOR CXCR4; DOPAMINE RECEPTOR STIMULATING AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROLACTIN; PROTEIN AGGF1; PROTEIN BTG1; PROTEIN FGF1; PROTEIN FGFBP1; PROTEIN FST; PROTEIN RHOB; PROTEIN SERPINE1; PROTEIN SERPINF1; PROTEIN STAB; QUINAGOLIDE; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIOSIS; FEMALE; FIBRINOLYSIS; FLUORESCENCE ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPROLACTINEMIA; IMMUNOHISTOCHEMISTRY; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SECOND LOOK SURGERY; TISSUE DEGENERATION; TREATMENT DURATION; UTERUS SURGERY; VOMITING;

EID: 79951955214     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2010.10.024     Document Type: Article

References (38)

1. Ozkan S, Arici A. Advances in treatment options of endometriosis. Gynecol Obstet Invest 2009;67:81-91.
2. Mihalyi A, Simsa P, Mutinda KC, Meuleman C, Mwenda JM. d'Hooghe TM. Emerging drugs in endometriosis. Expert Opin Emerg Drugs 2006;11:503-24.
3. Bruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab 2009;94:2489-94.
4. Shifren JL, Tseng JF, Zaloudek CJ, Ryan IP, Meng YG, Ferrara N, et al. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996;81:3112-8. (Pubitemid 26323917)
5. McLaren J, Prentice A, Charnock-Jones DS, Millican SA,M€uller KH, Sharkey AM, et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 1996;98:482-9. (Pubitemid 26255749)
6. Nap AW, Griffioen AW, Dunselman GA, Bouma-ter Steege JC, Thijssen VL, Evers JL, et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004;89:1089-95. (Pubitemid 38368395)
7. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M,Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-36. (Pubitemid 351398487)
8. Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra RB, Dasgupta PS, et al. Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res 2004;64:5551-5. (Pubitemid 39095547)
9. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001;7:569-74. (Pubitemid 32448324)
10. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996;10:333-7. (Pubitemid 26310263)
11. Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002;16:791-3. (Pubitemid 35278500)
12. Novella-Maestre E, Carda C, Noguera I, Ruiz-Saurí A, Garcia-Velasco JA, Simon C, et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod 2009;24:1025-35.
13. Vance ML, Cragun JR, Reimnitz C, Chang RJ, Rashef E, Blackwell RE. CV 205-502 treatment of hyperprolactinemia. J Clin Endocrinol Metab 1989;8:336-9.
14. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931-7. (Pubitemid 47236352)
15. Busso C, Fernández-Sánchez M, García-Velasco JA, Landeras J, Ballesteros A, Muñoz E, et al. The nonergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod 2010;25:995-1004.
16. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400-11. (Pubitemid 44790595)
17. Hoshiai H, Ishikawa M, Sawatari Y, Noda K, Fukaya T. Laparoscopic evaluation of the onset and progression of endometriosis. Am J Obstet Gynecol 1993;169:714-9. (Pubitemid 23290197)
18. Thomas EJ, Cooke ID. Impact of gestrinone on the course of asymptomatic endometriosis. Br Med J 1987;294:272-4. (Pubitemid 17006321)
19. Kurt M, Ibis M, Karaman K, Bostanci EB, Temucin T. Rectal endometriosis and prolactinoma. Hum Reprod 2010;25:1588-9.
20. Krikun G, Hu Z, Osteen K, Bruner-Tran KL, Schatz F, Taylor HS, et al. The immunoconjugate "icon" targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol 2010;176:1050-6.
21. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-Jones D, et al. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroinmunol 2002;132:34-40. (Pubitemid 35333323)
22. Cristina C, Díaz-Torga G, Baldi A, Góngora A, Rubinstein M, Low MJ, et al. Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. Endocrinology 2005;146:2952-62. (Pubitemid 41002802)
23. Chakroborty D, Chowdhury UR, Sarkar C, Baral R, Dasgupta PS, Basu S. Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J Clin Invest 2008;118:1380-9. (Pubitemid 351500431)
24. Sookhai S, Wang JH, McCourt M, O'Connell D, Redmond HP. Dopamine induces neutrophil apoptosis through a dopamine D-1 receptor-independent mechanism. Surgery 1999;126:314-22. (Pubitemid 29382797)
25. Oral E, Olive DL, Arici A. The peritoneal environment in endometriosis. Hum Reprod Update 1996;2:385-98. (Pubitemid 27087175)
26. Kyama CM, Mihalyi A, Simsa P, Falconer H, Fulop V, Mwenda J, et al. Role of cytokines in the endometrial-peritoneal cross-talk and development of endometriosis. Front Biosci 2009;1:444-54.
27. Yoshino O, Osuga Y, Koga K, Hirota Y, Tsutsumi O, Yano T, et al. Concentrations of interferon-gamma-induced protein-10 (IP-10), an antiangiogenic substance, are decreased in peritoneal fluid of women with advanced endometriosis. Am J Reprod Immunol 2003;50:60-5. (Pubitemid 36805765)
28. Ulukus M, Ulukus EC, Tavmergen Goker EN, Tavmergen E, Zheng W, Arici A. Expression of interleukin-8 and monocyte chemotactic protein 1 in women with endometriosis. Fertil Steril 2009;91:687-93.
29. Konno R, Fujiwara H, Netsu S, Odagiri K, Shimane M, Nomura H, et al. Gene expression profiling of the rat endometriosis model. Am J Reprod Immunol 2007;58:330-43. (Pubitemid 47382231)
30. Tian XL, Kadaba R, You SA, Liu M, Timur AA, Yang L, et al. Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature 2004;427:640-5. (Pubitemid 38248484)
31. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990;172:1535-45.
32. Gregoriou O, Konidaris S, Vitoratos N, Papadias C, Papoulias I, Chryssicopoulos A. Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Int J Fertil Womens Med 1997;42:406-11.
33. Walch K, Unfried G, Huber J, Kurz C, van Trotsenburg M, Pernicka E. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis - a pilot study. Contraception 2009;79:29-34.
34. Negishi H, Furuta I, Ushigoe K, Fujimoto S, Koide SS. In vitro production of progesterone and estradiol by rat granulosa cells regulated by cabergoline and prolactin. Endocr Res 1998;24:195-203.
35. Sauder SE, Frager M, Case GD, Kelch RP, Marshall JC. Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine. J Clin Endocrinol Metab 1984;59:941-8. (Pubitemid 14020697)
36. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220-40.
37. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6-7.
38. Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 2002;11:787-800. (Pubitemid 34618811)